期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 17, 页码 7459-7475出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b00805
关键词
-
资金
- National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning [2014M3C9A-2064603, 2015R1A2A2A01008408, 370C-20160046]
- NIDDK [ZIA DK031117]
- Seoul National University (SNU)
- National Research Foundation of Korea [2015R1A2A2A01008408] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
A(3) adenosine receptor (AR) ligands including A(3) AR agonist, N-6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (1a, IB-MEGA) were examined for adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs). In this model, 1a significantly increased adiponectin production, which is associated with improved insulin sensitivity. However, A(3) AR antagonists also promoted adiponectin production in hBM-MSCs, indicating that the A(3) AR pathway may not be directly involved in the adiponectin promoting activity. In a target deconvolution study, their adiponectin-promoting activity was significantly correlated to their binding activity to both peroxisome proliferator activated receptor (PPAR) gamma and PPAR delta. They functioned as both PPAR gamma partial agonists and PPAR delta antagonists. In the diabetic mouse model, la and its structural analogues A(3) AR antagonists significantly decreased the serum levels of glucose and triglyceride, supporting their antidiabetic potential. These findings indicate that the polypharmacophore of these compounds may provide therapeutic insight into their multipotent efficacy against various human diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据